Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease

American Regent, Inc.50 enrolled

Overview

The current registry is being undertaken to assess the long-term (12 month) safety and tolerability of Venofer in the pediatric population with chronic kidney disease that requires intravenous iron maintenance therapy.

This will be a multicenter, observational, prospective registry collecting long-term (12-month) safety, tolerability, and laboratory data. Subjects will be screened for inclusion criteria if on hemodialysis (HD), peritoneal dialysis (PD) or have non-dialysis dependent (NDD) chronic kidney disease (CKD). Treatment-emergent adverse events (adverse events starting from the time of the 1st dose of Venofer administered on study) will be collected via site entry of data into a web-based system. Each research investigator will be responsible for entering adverse event information on the appropriate clinical research form as well as reporting such events to the sponsor. Number of Subjects: 50 evaluable subjects (i.e., took at lease one dose of Venofer and have safety data recorded at the 12 month time point).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Chronic Kidney Disease

Eligibility

Sex: ALLMin age: 2 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age greater than or equal to 2 to less than or equal to 17 years * Subjects must have a diagnosis of either NDD-CKD, PD-CKD or HD-CKD * Dialysis patients must be on a stable periotoneal (PD) or hemodialysis (HD) regimen for 1 month * Patient agrees to participate in the registry (i.e., provide adverse event information) for 12 months Exclusion Criteria: \-

Locations (9)

Stanford University

Palo Alto, California, United States

Nemours Orlando A.I. DuPont Hospital for Children

Jacksonville, Florida, United States

University of Miami

Miami, Florida, United States

University of Iowa

Outcomes

Primary Outcomes

Treatment- emergent adverse events (TEAE)

Adverse Events starting from from the 1st dose of Venofer adminstered on study through 12 month observation

Time frame: 1st Venofer dose through 12 month observation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.